Corbus Pharmaceuticals Holdings, Inc. (CRBP) Earnings History
Annual and quarterly earnings data from 2012 to 2025
Loading earnings history...
CRBP EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
CRBP Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | -85.9% | -6350.1% | -5166.4% |
Download Data
Export CRBP earnings history in CSV or JSON format
Free sign-in required to download data
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Earnings Overview
As of May 8, 2026, Corbus Pharmaceuticals Holdings, Inc. (CRBP) reported trailing twelve-month net income of -$79M, reflecting -60.3% year-over-year growth. The company earned $-5.90 per diluted share over the past four quarters.
Looking at the long-term picture, CRBP's historical earnings data spans multiple years. The company achieved its highest annual net income of -$887 in fiscal 2012.
Corbus Pharmaceuticals Holdings, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including AGIO (-$423M net income, -764.0% margin), RCUS (-$369M net income, -142.9% margin), IMVT (-$464M net income), CRBP has comparable earnings metrics. Compare CRBP vs AGIO →
CRBP Earnings vs Peers
Earnings metrics vs comparable public companies
CRBP Historical Earnings Data (2012–2025)
14 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$79M | -95.3% | -$85M | $-5.90 | - | - |
| 2024 | -$40M | +9.9% | -$49M | $-3.68 | - | - |
| 2023 | -$45M | +20.1% | -$45M | $-10.31 | - | - |
| 2022 | -$56M | -22.6% | -$35M | $-10.15 | - | - |
| 2021 | -$46M | +59.1% | -$56M | $-11.11 | -5166.4% | -6350.1% |
| 2020 | -$111M | -55.7% | -$123M | $-42.74 | -2826.1% | -3119.2% |
| 2019 | -$71M | -28.3% | -$77M | $-32.47 | -197.7% | -213.3% |
| 2018 | -$56M | -71.7% | -$57M | $-29.30 | -1154.5% | -1176.8% |
| 2017 | -$32M | -62.1% | -$33M | $-19.38 | -1328.6% | -1334.4% |
| 2016 | -$20M | -126.0% | -$20M | $-14.58 | -1046.3% | -1045.6% |
See CRBP's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CRBP Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CRBP vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCRBP — Frequently Asked Questions
Quick answers to the most common questions about buying CRBP stock.
Is CRBP growing earnings?
CRBP EPS fell to $-5.90, with earnings declining -60.3%. This contrasts with the 5-year CAGR of N/A. TTM net income dropped to $-79M.
What are CRBP's profit margins?
Corbus Pharmaceuticals Holdings, Inc. net margin is N/A, with operating margin at N/A. Below-average margins reflect competitive or cost pressures.
How consistent are CRBP's earnings?
CRBP earnings data spans 2012-2025. The declining earnings trend is -60.3% YoY. Historical data enables comparison across business cycles.